Navigation Links
Pacific Biomarkers, Inc. Schedules Second Quarter Conference Call for Friday, February 12, 2010
Date:2/9/2010

SEATTLE, Feb. 9 /PRNewswire-FirstCall/ -- Pacific Biomarkers, Inc. (OTC Bulletin Board: PBME), which provides specialty reference biomarker services to support pharmaceutical and laboratory diagnostic manufacturers in the conduct of human clinical research, today announced that it has scheduled an investor conference call for 11:15 a.m. EST (8:15 a.m. PST) on Friday, February 12, 2010 to review the Company's operating results for the second quarter and first half of FY2010. The Company intends to report its operating results prior to the conference call.

The Company also announced that its corporate name has been officially changed to Pacific Biomarkers, Inc. The name was approved by shareholders and the State of Washington in December 2009. At the present time, the Company is waiting for a pending change in its stock symbol. In the meantime, the shares continue to trade on the OTC Bulletin Board under the symbol "PBME".

Investor Conference Call

Shareholders and other interested parties may participate in the investor conference call by dialing 800-860-2442 (international/local participants dial 412-858-4600) and requesting participation in the "Pacific Biomarkers, Inc. Conference Call" a few minutes before 11:15 A.m. EST on February 12, 2010. A replay of the conference call will be available one hour after the call through Friday, February 19, 2010 at 5:00 p.m. EDT by dialing 877-344-7529 (international/local participants dial 412-317-0088) and entering the Conference ID # 437808.

About Pacific Biomarkers, Inc. (PBI)

Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The Company provides expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, New York State, and the Lipid Standardization Program. PBI's clients include many of the world's largest pharmaceutical, biotech, and diagnostic companies. PBI also provides clinical biomarker services focusing on the emerging field of biomarker assay development and testing. Services include validating and performing ligand-binding assays for novel clinical biomarkers, immunogenicity testing, cell based assay testing and multiplex testing.

PBI is headquartered in Seattle, Washington, and its common stock trades on the OTC Bulletin Board under the symbol "PBME". For more information about PBI, visit the company's web site at www.pacbio.com.

SOURCE Pacific Biometrics, Inc.

RELATED LINKS
http://www.pacbio.com/

'/>"/>

SOURCE Pacific Biometrics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. Freshwater supplies threatened in central Pacific
2. Environmental setting of human migrations in the circum-Pacific Region
3. Quakes under Pacific floor reveal unexpected circulatory system
4. Worlds largest marine protected area created in Pacific Ocean
5. New study finds most North Pacific humpback whale populations rebounding
6. Pacific coast turning more acidic
7. NOAA study shows eastern tropical pacific ocean dolphin populations improving
8. Parasites outweigh predators in Pacific Coast estuaries
9. Pacific shellfish ready to invade Atlantic
10. Robot vehicle surveys deep sea off Pacific Northwest
11. Scientists discover a new Pacific iguana
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
(Date:3/24/2017)... -- Research and Markets has announced the addition of ... - Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle ... around 15.1% over the next decade to reach approximately $1,580 million ... estimates and forecasts for all the given segments on global as ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... ... prospective clinical study that demonstrates the accuracy of the FebriDx® test, a ... significant acute bacterial and viral respiratory tract infections by testing the body’s ...
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity ... for performing systematic gain-of-function studies. , This complement to loss-of-function studies, such ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... (ADC) therapeutics, today confirmed licensing rights that give it exclusive global access ... developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, an ...
Breaking Biology Technology: